What’s inside
View ResearchExplore how COVID-19 symptoms and severity impact people with multiple sclerosis (pwMS) undergoing immunotherapy. This analysis of the COVID-19 in MS Global Data Sharing Initiative dataset highlights that comorbidities like neuromuscular disorders, hypertension, chronic kidney disease, and immunodeficiency significantly influence COVID-19 outcomes. However, the type of MS and the efficacy of disease-modifying therapies do not significantly affect COVID-19 severity in this cohort.
COVID-19 Symptoms in MS Patients on Immunotherapy
Analyzing COVID-19 symptoms and severity in MS patients undergoing immunotherapy.
Impact of Comorbidities on COVID-19 in MS
Study highlights comorbidities like hypertension and CKD as key factors in COVID-19 severity for MS patients.
Role of Disease-Modifying Therapies in MS and COVID-19
Investigating how various DMTs influence COVID-19 outcomes in multiple sclerosis patients.
COVID-19 Outcomes in Multiple Sclerosis
Evaluating COVID-19 hospitalization rates and ICU admissions in people with multiple sclerosis.
Gender and Age Factors in MS and COVID-19
Examining the influence of gender and age on COVID-19 severity in MS patients.
Comprehensive COVID-19 Data Analysis in MS
Using global data to assess COVID-19's impact on multiple sclerosis patients, focusing on immunotherapy and comorbidities.
.svg)
.jpg)
.webp)
